Tag: long-acting injectable antipsychotics

A new survey of patients and healthcare professionals from the phase 3 SOLARIS trial finds strong satisfaction with a once-monthly ...

Schizophrenia care may be entering a more integrated phase as researchers examine what happens when long-acting injectable antipsychotics are combined ...

A groundbreaking clinical study has unveiled critical insights into the pharmacokinetics, safety, and tolerability of Aripiprazole once-monthly (AOM), a long-acting ...

In recent years, the challenge of ensuring consistent adherence to antipsychotic medication among patients with serious mental illness has remained ...

The realm of schizophrenia treatment has witnessed a compelling advancement with recent research highlighting the potential of paliperidone palmitate once-monthly ...

In the realm of psychiatric treatment, the pursuit of long-term efficacy and patient adherence remains a formidable challenge. A recent ...

In the complex landscape of psychosis treatment, the decision between prescribing oral antipsychotic medications or long-acting injectable (LAI) therapies has ...